Serum prostate specific antigen as pre-screening test for prostate cancer

Area of Science:

• Urology
• Oncology
• Diagnostic Medicine

Background:

• Prostate cancer is the most common cancer in North American men and a leading cause of cancer death.
• Effective early detection methods are vital as curative therapies are stage-dependent.
• Current screening involves digital rectal examination, transrectal ultrasonography, and serum prostate-specific antigen (PSA) measurements.

Purpose of the Study:

• To evaluate the efficacy of serum PSA levels as a pre-screening tool for prostate cancer.
• To determine an optimal serum PSA threshold for identifying men at higher risk of prostate cancer.
• To assess the cost-effectiveness of using serum PSA as an initial screening step.

Main Methods:

• A screening program involving 1,002 men aged 45-80 was conducted.
• Participants underwent digital rectal examination, transrectal ultrasonography, and serum PSA measurements.
• Various serum PSA cutoff values were analyzed to find the optimal threshold for risk stratification.

Main Results:

• A serum PSA threshold of 3.0 micrograms/L demonstrated 80.7% sensitivity and 89.6% specificity.
• The area under the receiver operating characteristic curve was 87.8%, indicating high accuracy.
• At this threshold, only 19% of the cohort required further expensive diagnostic procedures, with a 98.6% negative predictive value.

Conclusions:

• Serum PSA measurement is an efficient and cost-effective pre-screening test for prostate cancer in the general population.
• A threshold of 3.0 micrograms/L effectively identifies men who warrant further, more invasive diagnostic procedures.
• This approach reduces unnecessary testing and focuses resources on individuals with a significantly higher risk of prostate cancer.